Table 1.
Randomized clinical trials for TED therapy utilizing GO-QOL and other QOL outcomes (alphabetical listing)
| Intervention | Comparator | Investigators | HQOL instrument | Clinical outcome | HQOL outcome |
|---|---|---|---|---|---|
| IV steroids high-dose | IV steroids moderate and low-dose | Bartalena et al | GO-QOL | Improved CAS and composite outcome | Improved similarly in all groups |
| Mycophenolate + IV steroids | IV steroids | Kahaly et al | GO-QOL | No difference at 12 weeks | Improved similarly in all groups |
| Octreotide | Placebo | Wemeau et al | SF-36 GO-QOL |
No clinical differences | Not reported |
| Rituximab | IV steroids | Salvi et al | GO-QOL | Not reported | |
| Selenium | Pentoxifylline Placebo |
Marcocci et al | GO-QOL | Improved CAS | Improved |
| Teprotumumab | Placebo | Smith et al | GO-QOL | Improved proptosis and CAS | Improved |
| Teprotumumab | Placebo | Douglas et al | GO-QOL | Improved proptosis and CAS | Improved |
| Tocilizumab | Placebo | Perez-Moreiras et al (ref) | SF-36 GO-QOL |
Improved proptosis and CAS | No difference Improved |
Abbreviations: CAS, clinical activity score; GO, Graves’ ophthalmopathy; HQOL, health-related quality of life; IV, intravenous; QOL, quality of life; TED, thyroid eye disease.